| Timothy Andrew Timmons, | |
|
2710s Rife Medical Ln, Rogers, AR 72758-1452 | |
| (479) 338-8000 | |
| (479) 338-2906 |
| Full Name | Timothy Andrew Timmons |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 23 Years |
| Location | 2710s Rife Medical Ln, Rogers, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376801712 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | E-9108 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Northwest Arkansas | Rogers, AR | Hospital |
| Mercy Hospital - Cassville | Cassville, MO | Hospital |
| Mercy Hospital Berryville | Berryville, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Health Northwest Arkansas Communities | 0648177873 | 265 |
News Archive
A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.
Cancers of all types become most deadly when they metastasize and spread tumors throughout the body. Once cancer has reached this stage, it becomes very difficult for doctors to locate and treat the numerous tumors that can develop.
On May 20, 2009, the US District Court for the District of New Jersey granted the request of AstraZeneca for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension) in the US. No trial date for the patent litigation has been set.
Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
› Verified 4 days ago
| Entity Name | Mercy Health Northwest Arkansas Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699076737 PECOS PAC ID: 0648177873 Enrollment ID: O20110330000454 |
News Archive
A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.
Cancers of all types become most deadly when they metastasize and spread tumors throughout the body. Once cancer has reached this stage, it becomes very difficult for doctors to locate and treat the numerous tumors that can develop.
On May 20, 2009, the US District Court for the District of New Jersey granted the request of AstraZeneca for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension) in the US. No trial date for the patent litigation has been set.
Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy Andrew Timmons, 2710s Rife Medical Ln, Rogers, AR 72758-1452 Ph: (479) 338-8000 | Timothy Andrew Timmons, 2710s Rife Medical Ln, Rogers, AR 72758-1452 Ph: (479) 338-8000 |
News Archive
A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.
Cancers of all types become most deadly when they metastasize and spread tumors throughout the body. Once cancer has reached this stage, it becomes very difficult for doctors to locate and treat the numerous tumors that can develop.
On May 20, 2009, the US District Court for the District of New Jersey granted the request of AstraZeneca for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension) in the US. No trial date for the patent litigation has been set.
Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.
› Verified 4 days ago
Manikandan Rajagopal, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2710 S Rife Medical Ln, Rogers, AR 72758 Phone: 479-338-8000 Fax: 479-338-2383 | |
Dr. Wendy S. David, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2710 S Rife Medical Ln, Rogers, AR 72758 Phone: 479-338-8000 Fax: 479-338-2906 | |
Dr. Mansoor Alam, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2710 S Rife Medical Ln, Rogers, AR 72758 Phone: 479-338-8000 Fax: 479-338-2383 | |
Dr. Cynthia Renee Wilson, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2710 Rife Medical Ln, Hospitalist, Rogers, AR 72758 Phone: 479-338-8000 Fax: 479-338-2906 | |
Dr. Robert William Donnell, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2710 Rife Medical Ln, Hospitalist, Rogers, AR 72758 Phone: 479-338-8000 Fax: 479-338-2906 | |
Stephanie Michelle Henkel, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2710s Rife Medical Ln, Rogers, AR 72758 Phone: 479-338-8000 Fax: 479-338-2916 | |
Dr. Ralph Courtney Ritz, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2710 Rife Medical Ln, Hospitalist, Rogers, AR 72758 Phone: 479-338-8000 Fax: 479-338-2906 |